Skip to main content

New Cancer Immunotherapy Shows Promise in Early Research Co-led by CPB Distinguished Professor

Dr. Ratliff works in a lab
Dr. Timothy L. Ratliff, the Robert Wallace Miller Director of the Purdue University Center for Cancer Research, is part of a team of scientists who have developed the first universal cancer treatment that targets non-malignant cells in tumors. (Purdue University photo)

A new approach to cancer immunotherapy has the potential to be a universal treatment for solid tumors, according to researchers at Purdue University, including a Distinguished Professor in Purdue Veterinary Medicine’s Department of Comparative Pathobiology.  The research was led by Dr. Philip Low, Purdue’s Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry, and Dr. Timothy Ratliff, Distinguished Professor of Comparative Pathobiology and the Robert Wallace Miller Director of the Purdue University Center for Cancer Research.

The two scientists collaborated to develop and test the new treatment that works not by attacking the cancer cells themselves, but by focusing on immune system cells that, ironically, feed the tumor and block other immune system cells from destroying it.  The first details of the approach were published recently in the journal Cancer Research.

Dr. Low said the treatment is “totally unique” and has been shown to work in six different tumor types. So far, the treatment has been tested in human tumor cells in the laboratory and in human tumors in animal models.  The approach targets immune cells that, in cancerous tumors, stop the body’s own defenses from killing the tumor. “We can reprogram the immune cells within the tumor to help kill the tumor instead of allowing these cells to help the tumor grow,” Dr. Low said.

Dr. Low pictured outside in front of a building at Purdue
Dr. Philip Low, Purdue’s Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry, is leading a team that has developed a new, universal cancer immunotherapy. (Purdue University photo)

In this technique, an anti-cancer drug that would normally be too toxic for human use is linked to folate, which is a type of vitamin B. Almost no normal cells have a receptor for the folate, so it passes on through the body, but certain cancer-associated immune cells do.

“We use the vitamin folate to target attached drugs specifically to these nonmalignant cells within a tumor mass that, unfortunately, promote tumor growth. These tumor-associated macrophages love folate,” Dr. Low said. “They have an enormous appetite for it. They take it up right away, and if they don’t, the compound passes in the urine within about 30 minutes. So, we ‘re using folate as a kind of Trojan horse to trick the tumor-promoting immune cells into eating a drug that will reprogram them into tumor-fighting immune cells.”

Dr. Ratliff explained that this treatment may prove to be more universally effective than current cancer immunotherapies.  “There are therapeutic antibodies that are used on some types of cancer. And many people have heard of checkpoint immunotherapies, which block certain parts of the immune response,” Dr. Ratliff said. “When I talk to groups, I always point out that former President Jimmy Carter had metastatic brain cancer, and he went through immunotherapy, and it eliminated the cancer for him.”

“But the problem is,” Dr. Ratliff continued, “that only about 20 percent of the patients actually respond. So, we need to take a different approach to modulating the immune response.”  Dr. Ratliff said the folate-targeted approach is exciting because it is the first research project that has found a way to target the cells that boost tumor growth in the tumor environment.

“These are cells that are important to the tumors, but they aren’t the tumor cells themselves,” Dr. Ratliff said. “By targeting these myeloid cells within the tumor, we have a universal process because these cells are present in all of the solid tumors.”

Dr. Low said the new immunotherapy treatment could be available to patients within a decade. “On average, this usually takes ten years, but we have a small team and we’re aggressive. So, I think there’s a reasonable chance this could make it to the public within seven years or something like that,” he said. “It would probably cost a couple hundred million dollars, at the very least, to develop and test this drug.”

“So it’s not going to be cheap, and it’s not going to be easy. But this drug has enormous potential to save many lives. So, we will do our best.”

Click here to view a complete news release about the research.

Writer(s): Steve Tally, Purdue News Service | pvmnews@purdue.edu

Recent Stories

DVM and Veterinary Technology students gain job opportunity insights at fall PVM Career Fair

Purdue Veterinary Medicine's Fall Career Fair brought veterinary and veterinary technology students together with employers on October 30 at the Purdue Memorial Union. Students explored career opportunities, internships and externships while meeting representatives from veterinary practices and organizations.

In Memory: Dr. Mary Beth Leininger (PU DVM ’67)

Purdue Veterinary Medicine remembers Dr. Mary Beth Leininger (DVM 1967), who died November 6, 2026, at age 83. The first woman elected president of the American Veterinary Medical Association, she spent nearly three decades in private practice and held leadership positions in veterinary medicine, industry and education.

“Paws Up” for Kayla Fuqua – brought to you by the PVM Wellness Committee

Kayla Fuqua, the day-shift Emergency and Critical Care receptionist at our veterinary hospital, is this week's Paws Up honoree. A colleague recognized her for supporting clients, coworkers and veterinary students, answering questions and helping her department during busy shifts.

MMAS Symposium at Purdue provides hands-on learning about Medicine of Mammalian and Avian Species

More than 80 participants joined Purdue Veterinary Medicine's 2026 Medicine of Mammalian and Avian Species Symposium on October 31 and November 1. Organized by the Exotic Animal Club, the two-day event combined presentations on exotic animal medicine with hands-on training in parrot handling, rabbit examinations, avian clinical pathology and other specialized topics.

Costumed characters boost Halloween spirits in Lynn Hall

Halloween brought Minions, the Lorax, Super Mario Bros. characters and plenty of other costumes to Purdue Veterinary Medicine. Students, faculty and staff celebrated with costume contests, trick-or-treating and a Halloween dessert competition in Lynn Hall, the Reed ADDL and the Veterinary Hospital.